主に非扁平上皮非小細胞肺癌（NSCLC）患者を対象とした、ソラフェニブの第3/第4選択プラセボ対照試験。

基本情報

NCT ID

NCT00863746

ステータス

完了

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

703

治験依頼者名

Bayer

概要

The purpose of the study is to see if sorafenib plus best supportive care (i.e. in addition to the non-cancer treatments patients would normally receive) is an effective treatment for lung cancer compared to best supportive care alone. The safety and tolerability of the two treatment groups will also be compared. The goal of the study is to test the ability of sorafenib to improve survival compared to best supportive care alone.

対象疾患

介入

依頼者（Sponsor）